Here you will find financial information related to Infant Bacterial Therapeutics AB.
The class B share of Infant Bacterial Therapeutics AB was listed on Nasdaq Stockholm First North on March 29, 2016 and approved to be listed on Nasdaq Stockholm First North Premier from March 14, 2017.
Our assessment is that the dividend of shares in Infant Bacterial therapeutics AB (IBT) is exempt from taxation in Sweden based on the s.c. Lex ASEA – rules. The cost of the shares in BioGaia which entitle dividend shall be allocated between those shares and received IBT shares. The allocation of cost shall be based on the change in value of the shares in BioGaia resulting from the dividend of the shares in IBT.
Skatteverket have provided guidance regarding allocation. See the enclosed link to the homepage of Skatteverket.
Erik Penser Bank
Phone: +46 (0)8 463 80 00